- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Crohn disease; Ulcerative colitis; Juvenile idiopathic arthritis; Fistulising Crohn disease; Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis; Chronic plaque psoriasis; Hidradenitis suppurativa
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Adalimumab – March 2020
Adalimumab: Injection 40 mg in 0.8 ml pre-filled syringe, 2; Injection 40 mg in 0.8 ml pre-filled pen, 2; Injection 40 mg in 0.8 ml pre-filled syringe, 6; Injection 40 mg in 0.8 ml pre-filled pen, 6; Hyrimoz®
Last updated
3 July 2020
